Alzheimer's disease (AD) is an incurable age-associated neurodegenerative disorder that is characterized by irreversible progressive cognitive deficits and extensive brain damage. The identification of candidate biomarkers before beta amyloid plaque deposition occurs is therefore of great importance for the early intervention of AD. Urine, which is not regulated by homeostatic mechanisms, theoretically accumulates changes associated with AD earlier than cerebrospinal fluid and blood. In this study, an APP (swe)/PSEN1dE9 transgenic mouse model was used to identify candidate biomarkers for early AD. Urine samples were collected from 4-, 6-, and 8-month-old transgenic mouse models, and the urinary proteomes were profiled using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). The levels of 33 proteins differed significantly between wild-type and 4-month-old mice, which had not started to deposit beta amyloid plaque. Among these proteins, 16 have been associated with the mechanisms of AD, while 9 have been suggested as AD biomarkers. Our results indicated that urine proteins enable detecting AD before beta amyloid plaque deposition, which may present an opportunity for intervention.
Figure 1. Characteristics of behavioral and pathological profiles of different stages of APP (swe)/PSEN1 dE9 transgenic mice
In this study, the APP (swe)/PSEN1 dE9 transgenic mouse model was used to identify candidate early AD biomarkers. To identify changes in the urinary proteome during AD development, we collected and analyzed urine samples of APP (swe)/PSEN1 dE9 transgenic mice at three growth stages (4-, 6-and 8-month-old). The workflow of the proteomic analysis in this study is shown in Figure 2 . By using label-free and TMT-labeling proteomics analysis, we analyzed differential urine biomarkers from different stages of AD.
Results and discussion

Urinary proteome changes in APP (swe)/PSEN1 dE9 transgenic mice
The urinary proteins of 4-month-old mice were digested by an in-gel method and quantified by a label-free method. A total number of 443 protein groups were identified in the urinary proteome at an FDR < 1%, and each generated at least 2 unique peptides. The levels of 33 urinary proteins were significantly different between the AD and wild-type groups ( Table 1) ; among these proteins, cadherin-16 levels were different in both the >85 kDa and 50-85 kDa lanes, sulfhydryl oxidase 1 levels were different in both the 50-80 kDa and 30-50 kDa lanes, and deoxyribonuclease-1 levels were different in both the 15-30 kDa and <15 kDa lanes. The fold change of the significantly changed protein levels was more than 1.5. In these 33 differential proteins, 17 had been reported to be associated with AD. Specifically, 15 had been reported to be associated with the pathology mechanisms of AD, while 9 were identified as direct AD biomarkers (Table 1) .
Seven proteins relate to the development of AD as well as biomarkers of AD. (1) Kallikrein-1 (KLK1) levels were different in 4-, 6-and 8-month-old groups than the wild-type group, and the kallikrein-kinin system mediates inflammation in AD in vivo [25] . Kallikrein-6, one member of the kallikrein family, was reported as a biomarker of AD and to have increased levels in CSF and serum and decreased levels in tissue [26] . (2) Galactocerebrosidase (GALC) levels were different in 4-and 8-month-old groups than the wild-type group, and a deficiency in galactosylceramidase potentially contributed to neurodegenerative disease [27] . Ceramide has been suggested to participate in the neuronal cell death that leads to AD. GALC, as a gene connected to ceramide metabolism, was upregulated in the brain tissue of AD patients, making it an attractive candidate for diagnostic purposes and for intervening in neurodegenerative processes [28] . (3) Ceruloplasmin (CERU) levels were higher in both 4-and 8-month-old groups than in the control group, with the same trend of increased levels found in the serum of AD patients [29] . The levels of CSF diagnostic markers, such as Aβ42, tau and phospho-tau, were correlated with lower plasma copper and CERU levels in patients with Alzheimer's disease [30] . The ratio of CERU concentrations measured by enzymatic methods (eCP) to those measured by immunological methods (iCP), eCP/iCP, reflects the high specificity of AD patients as well as a decreased risk of having AD [31] . CERU had less ferroxidase activity in AD patients than wild-type patients, which contributed to the development of AD [32] . (4) Fibronectin (FINC) levels were different in 4-and 8-month-old groups than in the wild-type group and were reported to be a novel biomarker for AD from blood [33] . In addition, FINC levels were significantly lower in plasma in mild cognitive impairment (MCI) patients than healthy patients, which provides further insight into the biological pathways and processes that underpin the pathophysiology and progression of MCI and AD [34] . (5) Cathepsin B (CATB) levels were different in 4-and 8-month-old groups than the wild-type group. CATB has been previously reported to be upregulated in brain tissues from APP/PS1 transgenic mice, and its levels changed in the same direction relative to healthy mice as they changed in the serum of AD patients relative to control patients, making CATB a potential biomarker of AD [13] .
In addition, CATB produces brain pyroglutamate amyloid beta, which represents a potential AD therapeutic [35] . (6) Angiotensinogen (ANGT) was upregulated in 4-month-old groups and has exhibited increased levels in the CSF of AD patients [36] . As a component of the renin-ANGT system (RAS), ANGT is helpful for AD processes [37] . (7) Annexin A11 (ANX11) was upregulated in 4-month-old groups. Annexin A1 was reported to be expressed strongly in the microglia of AD patients, which aids the surveillance of microglia and the maintenance of brain homeostasis by using Annexin A1-dependent mechanisms [38] , and Annexin A5 was reported to be a biomarker of AD and present at increased levels in the plasma of AD patients [39] . The protein-normalized abundances and spectral counts of all seven differential proteins were greater in every mouse in the high-abundance group than those in the low-abundance group.
Two other differential proteins have been mentioned as potential AD biomarkers. (1) Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) levels were higher in the CSF of AD patients than the CSF of healthy controls. ENPP2 can be used to specifically discriminate AD from Lewy body dementia, making it a candidate AD biomarker [40] . (2) The Ig kappa chain C (IGKC) region was reported to be a potential serum biomarker of AD at the early stage [41] .
Eight differential proteins are associated with the mechanism of AD pathology. (1) CDH1, the gene of cadherin-1, is an AD risk gene that has significant association in Caribbean Hispanic individuals [42] .
(2) As glycosylated transmembrane proteins, cadherins such as cadherin-1 and cadherin-16 also directly interact with the presenilin-1/g-secretase complex, which contributes to the modulation of Aβ peptide formation and thus plays a critical role in AD etiology [43] . (3) Alpha-amylase 1 (AMY1) reflects M3 muscarinic agonist activity in AD [44] . (4) ASMase, the gene of sphingomyelin phosphodiesterase, which is connected to ceramide metabolism, was upregulated in the brain tissue of AD patients, making it an attractive candidate for both diagnostic purposes and intervening in neurodegenerative processes [28] . Significant correlations were observed between brain sphingomyelin phosphodiesterase levels and the levels of amyloid beta peptide (Aβ) and phosphorylated tau protein, which contribute to AD disease pathogenesis [45] . (5) Platelet-activating factor acetylhydrolase (PAFA) was present in higher levels in the plasma of AD patients than that of healthy controls, and these higher levels were associated with oxidative damage of low-density lipoproteins (ox-LDL), which contributes to the inflammation and oxidative stress of plasma lipoproteins and is strongly associated with Alzheimer's disease [46] . (6) Plasma carbonic anhydrase 2 (CAH2) was elevated in AD patients and may thus play a role in the pathogenesis of AD [47] . (7) Acid ceramidase (ASAH1) levels were elevated in AD brain, suggesting that acid ceramidase might play a role in controlling neuronal apoptosis and that acid ceramidase-mediated signaling pathways might be involved in the molecular mechanism of AD [48] . (8) Lipoprotein lipase (LIPL) is associated with neurite pathology, and its levels were reduced in the dentate gyrus of AD brains [49] . Some differential proteins have not been reported in research papers and may provide clues to candidates involved in the AD pathology mechanism. The urinary proteins of 6-month-old mice were digested by a filter-aided method and quantified by a TMT-labeling method. At the protein level, 310 protein groups were identified in the urinary proteome at an FDR < 1%, and each generated at least 2 unique peptides. The levels of 33 urinary proteins were significantly different between the AD and wild-type groups, and their fold changes were greater than 1.5. Eight of these 33 differential proteins had been reported to be associated with AD. To be specific, 6 were associated with the pathology mechanisms of AD, while 3 had been directly referred to be AD biomarkers ( Table 2) .
Three differential proteins (KLK1, IGKC, and RAB10) have been suggested as AD biomarkers. The target gene RAB10, which is regulated by miRNA-369-3p, miRNA-30e-5p, miRNA-30e-3p, and miRNA-655, may play key roles in the progression and development of AD and may be a biomarker of AD[50].
Six differential proteins are associated with the mechanism of AD pathology. Charged multivesicular body protein 2a (CHM2A) levels were elevated in the 6-month-old group.
Mutations in charged multivesicular body protein 2B (CHMP2B) can give rise to FTLD-UPS[52]. (3)
Peroxisomal carnitine (OCTC) levels were higher in the 6-month-old group than the wild-type group, and new therapies acting on peroxisomal metabolism might be developed to prevent cognitive decline and other age-related neurological disorders[53]. (4) Heat shock cognate 71 kDa protein (HSP7C) was upregulated in 6-month-old groups, while its gene level was significantly lower across the three brain regions in AD patients than in controls patients, suggesting their participation in AD pathogenesis [54] . (5) Cooperative expression of leukemia inhibitory factor (LIF) and its receptor (LIFR) in AD hippocampus may indicate a role for LIF in neuronal damage or repair at these sites [55] .
The urinary proteins of 8-month-old mice were digested by an in-gel method and quantified by a label-free method. At the protein level, 273 proteins were identified in the urinary proteome at an FDR < 1%, and each generated at least 2 unique peptides. The levels of 89 urinary proteins were significantly different between the AD and wild-type groups. Thirty-three of these 89 differential proteins have been associated with AD. Specifically, 29 are associated with the mechanism of AD pathology, while 17 have been suggested as candidate AD biomarkers. (Table 3) Thirteen proteins have been previously reported to be related to the development of AD as well as biomarkers of AD, while 5 of them (KLK1, GALC, CERU, FINC, and CATB) had been already noted in 4-month-old groups. For example, (1) Serum albumin (ALBU) was differentially expressed between brains of AD mouse models and those of healthy mice [56] , and serum levels of albumin-amyloid beta complexes were lower in AD patients than healthy controls, which is very useful to apply in monitoring the progression of AD [57] . (2) Clusterin (CLUS) levels were higher in AD patients than controls, especially in regions with most abundant in Aβ, facilitating the development of AD [58] . As a heterodimeric glycoprotein, clusterin was more abundant in the CSF of some neurodegenerative disease patients than that of healthy controls and could thus serve as a potential biomarker to differentiate Parkinson's disease (PD) from dementia with Lewy bodies (DLB) [59] . (3) CSF complement C3 (CO3) is a staging biomarker in AD [60] . In addition, the dysregulation of neuron-glia interactions through NFB/ C3/C3aR signaling may contribute to synaptic dysfunction in AD [61] .
Seventeen differential proteins have been mentioned as potential AD biomarkers. For example, (1) sulfated glycoprotein 1 (SAP) is a novel CSF biomarker for neurodegeneration and has been validated by a high-throughput multiplexed targeted proteomic assay [40] . (2) Cystatin-C (CYTC) is a novel CSF biomarker for staging early AD [62] . Twenty-nine differential proteins are associated with the mechanism of AD pathology. For example, (1) CD44 antigen (CD44) gene expression was greater in lymphocytes derived from AD patients than in those from healthy controls, suggesting that it plays roles in the peripheral immune response during the development of AD [63] . (2) The rs2227564 polymorphism of the urokinase-type plasminogen activator (UROK) gene increased the risk of AD [64] .
Other differential proteins are annotated in Table 3 . Functional annotation of differential urinary proteins was performed using DAVID [65] . The differential proteins at three time points were classified to be involved with certain biological processes ( Figure 4 ), molecular components, and molecular functions (Supplemental Figures 1 and 2) .
Functional analysis of differential urine proteins in APP (swe)/PSEN1 dE9 transgenic mouse
In 4-month-old mice, differential urine proteins involved in lipid metabolism and lipid catabolism were enriched. As lipid metabolism is a fundamental process for brain development and function, aberrant lipid metabolism was not surprisingly common in an animal model of AD that relates to AD pathogenesis [66] [67] [68] . For example, AD-induced perturbation of niche fatty acid metabolism can suppress the homeostatic and regenerative functions of neural stem cells, supporting the mechanism of AD pathogenesis [66] . Abnormal lipid metabolism influences Aβ metabolism and deposition in both brain parenchyma and vasculature, as well as tau hyperphosphorylation and aggregation, which then likely triggers a series of downstream catalytic events that eventually affect the progression of AD pathogenesis [67] . More importantly, lipid rafts from human cerebral cortex are associated with the pathogenesis of early AD, as -secretase/APP (amyloid-protein precursor) interactions and lipid raft microviscosity are strongly and positively correlated in AD frontal and entorhinal cortices, indicating that the aberrant lipid metabolism had already occurred in the early stage of AD [69] . Decidualization and calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules, which are not reported in AD studies, may play roles in the mechanism of AD pathology. Recent studies demonstrated that using a triple receptor agonist (TA), which activates GIP-1, GIP and glucagon receptors at the same time, reduces the total amount of beta amyloid in an APP/PS1 transgenic mouse model through a 2-month TA treatment [70] . However, this research used 6-month-old transgenic mice for a 2-month treatment, and beta amyloid had already appeared. We thus suppose that a more effective treatment can be achieved when the 4-month-old transgenic mice are used for therapy.
The differential proteins in 6-month-old mice were involved in transport processes, while axonal transport (AT) defects play an important role in the pathogenesis of AD [71] . Other biological processes such as microvillus assembly, the regulation of cell shape and protein localization to the plasma membrane may contribute to the formation of beta amyloid plaque deposits in the brain of AD patients, which provides potential clues for the studying the mechanism of AD.
A larger number of differential urine proteins were identified in 8-month-old mice and indicated other AD-related biological processes. Proteolysis processes were overrepresented and reported to be associated with APP proteolysis, which is consistent with the pathology of AD [72] . In addition, the urinary proteins that were related to fibrinolysis may be factors contributing to AD [73] . What's more, lysosome organization accumulated at amyloid plaques in mouse models of AD, which gave rise to potential therapies of AD patients [74] . Lastly, angiogenesis processes were reported to contribute to the pathogenesis of AD, as they are a common feature of amyloid beta (Aβ) plaques [75, 76] , and the levels of some angiogenesis factors were elevated in the plasma of AD patients [77] .
In summary, in the biological process category, metabolic and carbohydrate metabolic processes were overrepresented in 4-and 8-month-old AD mice. The differential urine proteins in 4-and 8-month-old mice indicated an enrichment of metabolic process, while the three subtypes of AD can be distinguished by metabolic profiling [78] . Considering that the biological processes whose activities changed in this experiment did not extensively overlap at these three time points, this result indicates that only three different stages might occur, implying that different therapeutic strategies may be appropriate for different stages. If biomarkers can be found in human as early as was found for the 4-month-old in this model, we may have an early intervention window in which disease development can be stopped.
In the cellular component category (Supplemental Figure 1 ), most differential proteins came from the extracellular exosome, the extracellular space, the anchored component of membranes, and blood microparticles, whereas a small number of differential proteins were derived from organelles such as the lysosome and the Golgi apparatus. In the molecular function category (Supplemental Figure 2) , hydrolase activity was overrepresented in 4-and 8-month-old mice; calcium ion binding was overrepresented in 4-month-old mice; protein complex binding, sodium ion transmembrane transporter activity and protein binding were overrepresented in 6-month-old mice; and peptidase, endopeptidase, serine-type peptidase activities were overrepresented in 8-month-old mice.
IPA of differential proteins in AD development
To identify the differential proteins with mostly affected cellular death and survival, ingenuity pathway analysis (IPA) was applied to cell death and survival networks ( Figure 5 ). Cadherin-1, which was reported to be associated with AD [42] , is a core component of these networks in 4-month-old mice.
CDH16, CP, ENPP2, AGT, SMPD1, PLA2G7 were upregulated and play roles in AD [28, 29, 36, 40, 43, 46] , whereas sialate O-acetylesterase was downregulated in 4-month-old mice. In 6-month-old mice, NEO1, CROT, GP2, SEMA4A and LIFR were present in higher levels in transgenic mice than the control group, and NEO1 as well as CROT were associated with the pathology and mechanism of AD[51, 79] . In contrast, MEP1B, CLIC4, and PDZK1 levels were lower in transgenic mice than the control group. FINC was the core component of the network in 8-month-old mice and plays roles in AD [80] . In addition, AFM, MFGE8, C3, CD44 and PLAU were upregulated in transgenic mice and are potential biomarkers or play roles in the development of AD [61, 63, 64, 81, 82] , while VNN1, HEXB and CTSZ were downregulated in transgenic mice when compared with control groups. 
Conclusion
Our results indicated that urine proteins enable AD early detection before beta amyloid plaque deposition, which may provide an opportunity for intervention. 
